• Update about state-of-the-art strategies for plaque modification in highly calcified coronary lesions

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Abiomed; AstraZenca; Bayer AG; Daiichi-Sankyo/Elil Lilly and Company; SIS Medical; Boehringer Ingelheim; Novartis</li><li>Grant Support/Research Contract - Abbott Vascular; Vifor; SIS Medical; Biosensors; Cordis Corporation, a Johnson & Johnson company</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Cordis Corporation, a Johnson & Johnson company; MedAlliance; NovoNordis; Amgen; Viatris; Sanofi</li></ul>